AURORA CANNABIS INC (ACB) Fundamental Analysis & Valuation

NASDAQ:ACB • CA05156X8504

Current stock price

3.44 USD
+0.15 (+4.56%)
At close:
3.44 USD
0 (0%)
After Hours:

This ACB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ACB Profitability Analysis

1.1 Basic Checks

  • In the past year ACB has reported negative net income.
  • ACB had a negative operating cash flow in the past year.
  • ACB had negative earnings in 4 of the past 5 years.
  • ACB had negative operating cash flow in 4 of the past 5 years.
ACB Yearly Net Income VS EBIT VS OCF VS FCFACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1B -2B -3B

1.2 Ratios

  • With a decent Return On Assets value of -11.45%, ACB is doing good in the industry, outperforming 65.97% of the companies in the same industry.
  • The Return On Equity of ACB (-16.55%) is better than 71.20% of its industry peers.
Industry RankSector Rank
ROA -11.45%
ROE -16.55%
ROIC N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ACB Yearly ROA, ROE, ROICACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

1.3 Margins

  • ACB has a Gross Margin (1.35%) which is in line with its industry peers.
  • ACB's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ACB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
ACB Yearly Profit, Operating, Gross MarginsACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ACB Health Analysis

2.1 Basic Checks

  • ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ACB has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ACB has less shares outstanding
  • The debt/assets ratio for ACB has been reduced compared to a year ago.
ACB Yearly Shares OutstandingACB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ACB Yearly Total Debt VS Total AssetsACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • ACB has an Altman-Z score of -10.50. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -10.50, ACB is not doing good in the industry: 76.44% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.06 indicates that ACB is not too dependend on debt financing.
  • ACB has a Debt to Equity ratio (0.06) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -10.5
ROIC/WACCN/A
WACC8.87%
ACB Yearly LT Debt VS Equity VS FCFACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

  • ACB has a Current Ratio of 3.06. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.06, ACB is in line with its industry, outperforming 51.83% of the companies in the same industry.
  • A Quick Ratio of 1.48 indicates that ACB should not have too much problems paying its short term obligations.
  • ACB has a worse Quick ratio (1.48) than 69.11% of its industry peers.
Industry RankSector Rank
Current Ratio 3.06
Quick Ratio 1.48
ACB Yearly Current Assets VS Current LiabilitesACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ACB Growth Analysis

3.1 Past

  • The earnings per share for ACB have decreased strongly by -502.65% in the last year.
  • The Revenue has grown by 16.54% in the past year. This is quite good.
  • The Revenue has been growing slightly by 6.94% on average over the past years.
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
Revenue 1Y (TTM)16.54%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%

3.2 Future

  • Based on estimates for the next years, ACB will show a very strong growth in Earnings Per Share. The EPS will grow by 103.58% on average per year.
  • ACB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.94% yearly.
EPS Next Y-2493.7%
EPS Next 2Y27.12%
EPS Next 3Y76.74%
EPS Next 5Y103.58%
Revenue Next Year5.63%
Revenue Next 2Y-0.69%
Revenue Next 3Y5.96%
Revenue Next 5Y1.94%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ACB Yearly Revenue VS EstimatesACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ACB Yearly EPS VS EstimatesACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. ACB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 58.22, which means the current valuation is very expensive for ACB.
  • ACB's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ACB is cheaper than 71.20% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.75, ACB is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 58.22
ACB Price Earnings VS Forward Price EarningsACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACB Per share dataACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • ACB's earnings are expected to grow with 76.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.12%
EPS Next 3Y76.74%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACB Dividend Analysis

5.1 Amount

  • ACB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACB Fundamentals: All Metrics, Ratios and Statistics

AURORA CANNABIS INC

NASDAQ:ACB (4/30/2026, 8:00:00 PM)

After market: 3.44 0 (0%)

3.44

+0.15 (+4.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength29.13
Industry Growth47.76
Earnings (Last)02-04
Earnings (Next)06-16
Inst Owners13.03%
Inst Owner Change0.2%
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap195.08M
Revenue(TTM)373.12M
Net Income(TTM)-88.74M
Analysts74
Price Target5.62 (63.37%)
Short Float %11.8%
Short Ratio6.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-336.98%
Min EPS beat(2)-587.94%
Max EPS beat(2)-86.02%
EPS beat(4)0
Avg EPS beat(4)-329.23%
Min EPS beat(4)-587.94%
Max EPS beat(4)-86.02%
EPS beat(8)2
Avg EPS beat(8)402.7%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.71%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.46%
Revenue beat(4)3
Avg Revenue beat(4)0.88%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)2.46%
Revenue beat(8)6
Avg Revenue beat(8)4.2%
Revenue beat(12)9
Avg Revenue beat(12)4.15%
Revenue beat(16)9
Avg Revenue beat(16)1.91%
PT rev (1m)8.15%
PT rev (3m)-1.78%
EPS NQ rev (1m)-70%
EPS NQ rev (3m)-355.03%
EPS NY rev (1m)-2.38%
EPS NY rev (3m)-62.33%
Revenue NQ rev (1m)-3.12%
Revenue NQ rev (3m)-20.65%
Revenue NY rev (1m)-0.54%
Revenue NY rev (3m)-4.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 58.22
P/S 0.71
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)0.06
Fwd EY1.72%
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS4.81
BVpS6.92
TBVpS6.13
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -11.45%
ROE -16.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.35%
FCFM N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score3
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.54%
Cap/Sales 5.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.06
Quick Ratio 1.48
Altman-Z -10.5
F-Score3
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
EPS Next Y-2493.7%
EPS Next 2Y27.12%
EPS Next 3Y76.74%
EPS Next 5Y103.58%
Revenue 1Y (TTM)16.54%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%
Revenue Next Year5.63%
Revenue Next 2Y-0.69%
Revenue Next 3Y5.96%
Revenue Next 5Y1.94%
EBIT growth 1Y-17.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.2%
EBIT Next 3Y33.11%
EBIT Next 5Y21.95%
FCF growth 1Y63.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.56%
OCF growth 3YN/A
OCF growth 5YN/A

AURORA CANNABIS INC / ACB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ACB.


What is the valuation status of AURORA CANNABIS INC (ACB) stock?

ChartMill assigns a valuation rating of 1 / 10 to AURORA CANNABIS INC (ACB). This can be considered as Overvalued.


How profitable is AURORA CANNABIS INC (ACB) stock?

AURORA CANNABIS INC (ACB) has a profitability rating of 1 / 10.


Can you provide the financial health for ACB stock?

The financial health rating of AURORA CANNABIS INC (ACB) is 3 / 10.